Journal
PHARMACEUTICAL RESEARCH
Volume 27, Issue 11, Pages 2307-2316Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-010-0179-6
Keywords
PAMAM dendrimer; camptothecin; drug delivery; colorectal cancer
Funding
- National Institutes of Health [R01-EB007470]
- Utah Science Technology and Research (USTAR) Initiative
Ask authors/readers for more resources
To synthesize and characterize a poly (amido amine) dendrimer-camptothecin (PAMAM-CPT) conjugate and evaluate its activity on human colorectal carcinoma cells (HCT-116). The attachment of CPT to amine-terminated PAMAM was facilitated through a succinic acid-glycine linker. The conjugate was characterized for absence of small molecular weight impurities, size and drug content. Stability of the conjugate in PBS and growth media and its in vitro activity on HCT-116 were studied. Cell cycle arrest and nuclear fragmentation upon PAMAM-CPT treatment were investigated. The conjugate was stable under physiological pH (7.4) in PBS and in growth media (with 10% FBS) with minimal release of 4% and 6% drug, respectively, at 48 h. PAMAM-CPT inhibited proliferation of HCT-116 cells with an IC50 value of 1.6 +/- 0.3 A mu M. The conjugate induced signs of cell cycle arrest with up to 68% of cells blocked in the G(2) phase. Confocal images of cells treated with PAMAM-CPT suggest nuclear fragmentation and formation of apoptotic bodies. Results show that the PAMAM-CPT conjugate was active against colorectal cancer cells in vitro, inhibiting their growth and inducing nuclear fragmentation. Coupled with the ability to target macromolecular therapeutics to tumors, this conjugate shows promise for cancer chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available